NEXT CHOICE- levonorgestrel tablet

Next Choice by

Drug Labeling and Warnings

Next Choice by is a Prescription medication manufactured, distributed, or labeled by Dispensing Solutions, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1  INDICATIONS AND USAGE

    Next ChoiceTM is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the first tablet should be taken as soon as possible within 72 hours of intercourse. The second tablet should be taken 12 hours later.

    Next ChoiceTM is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older.

    Next ChoiceTM is not indicated for routine use as a contraceptive.

  • 2  DOSAGE AND ADMINISTRATION

    Take one levonorgestrel tablet orally as soon as possible within 72 hours after unprotected intercourse or a known or suspected contraceptive failure. Efficacy is better if the tablet is taken as soon as possible after unprotected intercourse. The second tablet should be taken 12 hours after the first dose. Next ChoiceTM can be used at any time during the menstrual cycle.

    If vomiting occurs within two hours of taking either dose of medication, consideration should be given to repeating the dose.

  • 3  DOSAGE FORMS AND STRENGTHS

    Each Next ChoiceTM tablet is supplied as a peach, round, bevel edged, flat faced tablet containing 0.75 mg of levonorgestrel and is embossed with “475” on one side and “WATSON” on the other side.

  • 4  CONTRAINDICATIONS

    Next ChoiceTM is contraindicated for use in the case of known or suspected pregnancy.

  • 5  WARNINGS AND PRECAUTIONS

    5.1 Ectopic Pregnancy

    Ectopic pregnancies account for approximately 2% of all reported pregnancies. Up to 10% of pregnancies reported in clinical studies of routine use of progestin-only contraceptives are ectopic.

    A history of ectopic pregnancy is not a contraindication to use of this emergency contraceptive method. Healthcare providers, however, should consider the possibility of an ectopic pregnancy in women who become pregnant or complain of lower abdominal pain after taking Next ChoiceTM. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking Next ChoiceTM.

    5.2 Existing Pregnancy

    Next ChoiceTM is not effective in terminating an existing pregnancy.

    5.3 Effects on Menses

    Some women may experience spotting a few days after taking Next ChoiceTM. Menstrual bleeding patterns are often irregular among women using progestin-only oral contraceptives and women using levonorgestrel for postcoital and emergency contraception. If there is a delay in the onset of expected menses beyond 1 week, consider the possibility of pregnancy.

    5.4 STI/HIV

    Next ChoiceTM does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs).

    5.5 Physical Examination and Follow-up

    A physical examination is not required prior to prescribing Next ChoiceTM. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking Next ChoiceTM.

    5.6 Fertility Following Discontinuation

    A rapid return of fertility is likely following treatment with Next ChoiceTM for emergency contraception; therefore, routine contraception should be continued or initiated as soon as possible following use of Next ChoiceTM to ensure ongoing prevention of pregnancy.

    5.7 Presence of FD&C Yellow #6

    Next ChoiceTM contains FD&C Yellow #6 as a color additive.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trial Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. A double-blind, controlled clinical trial in 1,955 evaluable women compared the efficacy and safety of levonorgestrel tablets (one 0.75 mg tablet of levonorgestrel taken within 72 hours of unprotected intercourse, and one tablet taken 12 hours later) to the Yuzpe regimen (two tablets each containing 0.25 mg levonorgestrel and 0.05 mg ethinyl estradiol, taken within 72 hours of intercourse, and two tablets taken 12 hours later).

    The most common adverse events (>10%) in the clinical trial for women receiving levonorgestrel tablets included menstrual changes (26%), nausea (23%), abdominal pain (18%), fatigue (17%), headache (17%), dizziness (11%), and breast tenderness (11%). Table 1 lists those adverse events that were reported in >5% of levonorgestrel tablets users.

    Table 1: Adverse Events in >5% of Women, by % Frequency
     Most Common Adverse Events Levonorgestrel
    N=977 (%)
     Nausea  23.1
     Abdominal Pain 17.6
     Fatigue 16.9
     Headache 16.8
     Heavier Menstrual Bleeding 13.8
     Lighter Menstrual Bleeding 12.5
     Dizziness 11.2
     Breast Tenderness 10.7
     Other complaints 9.7
     Vomiting 5.6
     Diarrhea 5.0

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of Next ChoiceTM. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Gastrointestinal Disorders

    Abdominal Pain, Nausea, Vomiting

    General Disorders and Administration Site Conditions

    Fatigue

    Nervous System Disorders

    Dizziness, Headache

    Reproductive System and Breast Disorders

    Dysmenorrhea, Irregular Menstruation, Oligomenorrhea, Pelvic Pain

  • 7 DRUG INTERACTIONS

    Drugs or herbal products that induce enzymes, including CYP3A4, that metabolize progestins may decrease the plasma concentrations of progestins, and may decrease the effectiveness of progestin-only pills. Some drugs or herbal products that may decrease the effectiveness of progestin-only pills include:

    • barbiturates
    • bosentan
    • carbamazepine
    • felbamate
    • griseofulvin
    • oxcarbazepine
    • phenytoin
    • rifampin
    • St. John’s wort
    • topiramate

    Significant changes (increase or decrease) in the plasma levels of the progestin have been noted in some cases of coadministration with HIV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors.

    Consult the labeling of all concurrently used drugs to obtain further information about interactions with progestin-only pills or the potential for enzyme alterations.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Many studies have found no harmful effects on fetal development associated with longterm use of contraceptive doses of oral progestins. The few studies of infant growth and development that have been conducted with progestin-only pills have not demonstrated significant adverse effects.

    8.3 Nursing Mothers

    In general, no adverse effects of progestin-only pills have been found on breastfeeding performance or on the health, growth or development of the infant. However, isolated post-marketing cases of decreased milk production have been reported. Small amounts of progestins pass into the breast milk of nursing mothers taking progestin-only pills for long-term contraception, resulting in detectable steroid levels in infant plasma.

    8.4 Pediatric Use

    Safety and efficacy of progestin-only pills for long-term contraception have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents less than 17 years and for users 17 years and older. Use of Next ChoiceTM emergency contraception before menarche is not indicated.

    8.5 Geriatric Use

    This product is not intended for use in postmenopausal women.

    8.6 Race

    No formal studies have evaluated the effect of race. However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception). The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown.

    8.7 Hepatic Impairment

    No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.

    8.8 Renal Impairment

    No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.

  • 9 DRUG ABUSE AND DEPENDENCE

    Levonorgestrel is not a controlled substance. There is no information about dependence associated with the use of Next ChoiceTM.

  • 10 OVERDOSAGE

    There are no data on overdosage of levonorgestrel tablets, although the common adverse event of nausea and associated vomiting may be anticipated.

  • 11 DESCRIPTION

    Each Next ChoiceTM tablet contains 0.75 mg of a single active steroid ingredient, levonorgestrel [18,19-Dinorpregn-4-en-20-yn-3-one-13-ethyl-1 7-hydroxy-, (17α)-(-)-], a totally synthetic progestogen. The inactive ingredients present are colloidal silicon dioxide, corn starch, FD&C Yellow #6, magnesium stearate, povidone, and lactose monohydrate. Levonorgestrel has a molecular weight of 312.45, and the following structural and molecular formulas:

    Levonorgestrel structural and molecular formula
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Emergency contraceptive pills are not effective if a woman is already pregnant. Next ChoiceTM is believed to act as an emergency contraceptive principally by preventing ovulation or fertilization (by altering tubal transport of sperm and/or ova). In addition, they may inhibit implantation (by altering the endometrium). It is not effective once the process of implantation has begun.

    12.3 Pharmacokinetics

    Absorption

    No specific investigation of the absolute bioavailability of levonorgestrel tablets in humans has been conducted. However, literature indicates that levonorgestrel is rapidly and completely absorbed after oral administration (bioavailability about 100%) and is not subject to first pass metabolism.

    After a single dose of levonorgestrel tablets (0.75 mg) administered to 16 women under fasting conditions, the mean maximum serum concentration of levonorgestrel was 14.1 ng/mL at an average of 1.6 hours. See Table 2.

    Table 2: Pharmacokinetic Parameter Values Following Single Dose Administration of Levonorgestrel Tablets 0.75 mg to Healthy Female Volunteers under Fasting Conditions
      Mean (± SD)
      Cmax Tmax CL Vd t1/2 AUCinf
      (ng/mL) (h) (L/h) (L) (h) (ng·hr/mL)
     Levonorgestrel 14.1 (7.7) 1.6 (0.7) 7.7 (2.7) 260.0 24.4 (5.3) 123.1 (50.1)

    Cmax = maximum concentration

    Tmax = time to maximum concentration

    CL = clearance

    Vd = volume of distribution

    t1/2 = elimination half life

    AUCinf = area under the drug concentration curve from time 0 to infinity

    Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of levonorgestrel has not been evaluated.

    Distribution

    The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg. It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.

    Metabolism

    Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma. Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16βhydroxylevonorgestrel. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.

    Excretion

    About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.

    Specific Populations

    Pediatric: This product is not intended for use in the premenarcheal population, and pharmacokinetic data are not available for this population.

    Geriatric: This product is not intended for use in postmenopausal women and pharmacokinetic data are not available for this population.

    Race: No formal studies have evaluated the effect of race on pharmacokinetics of levonorgestrel tablets. However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets and the Yuzpe regimen (another form of emergency contraception). The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown [see USE IN SPECIFIC POPULATIONS (8.6)].

    Hepatic Impairment: No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablets.

    Renal Impairment: No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablets.

    Drug-Drug Interactions

    No formal drug-drug interaction studies were conducted with levonorgestrel tablets [see DRUG INTERACTIONS (7)].

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenicity: There is no evidence of increased risk of cancer with short-term use of progestins. There was no increase in tumorgenicity following administration of levonorgestrel to rats for 2 years at approximately 5 μg/day, to dogs for 7 years at up to 0.125 mg/kg/day, or to rhesus monkeys for 10 years at up to 250 μg/kg/day. In another 7 year dog study, administration of levonorgestrel at 0.5 mg/kg/day did increase the number of mammary adenomas in treated dogs compared to controls. There were no malignancies.

    Genotoxicity: Levonorgestrel was not found to be mutagenic or genotoxic in the Ames Assay, in vitro mammalian culture assays utilizing mouse lymphoma cells and Chinese hamster ovary cells, and in an in vivo micronucleus assay in mice.

    Fertility: There are no irreversible effects on fertility following cessation of exposures to levonorgestrel or progestins in general.

  • 14 CLINICAL STUDIES

    A double-blind, randomized, multinational controlled clinical trial in 1,955 evaluable women (mean age 27) compared the efficacy and safety of levonorgestrel tablets (one 0.75 mg tablet of levonorgestrel taken within 72 hours of unprotected intercourse, and one tablet taken 12 hours later) to the Yuzpe regimen (two tablets each containing 0.25 mg levonorgestrel and 0.05 mg ethinyl estradiol, taken within 72 hours of intercourse, and two additional tablets taken 12 hours later). After a single act of intercourse occurring anytime during the menstrual cycle, the expected pregnancy rate of 8% (with no contraceptive use) was reduced to approximately 1% with levonorgestrel tablets.

    Emergency contraceptives are not as effective as routine hormonal contraception since their failure rate, while low based on a single use, would accumulate over time with repeated use [see INDICATIONS AND USAGE (1)].

    At the time of expected menses, approximately 74% of women using levonorgestrel tablets had vaginal bleeding similar to their normal menses, 14% bled more than usual, and 12% bled less than usual. The majority of women (87%) had their next menstrual period at the expected time or within + 7 days, while 13% had a delay of more than 7 days beyond the anticipated onset of menses.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Next ChoiceTM (levonorgestrel) tablets, 0.75 mg, are available for a single course of treatment in PVC/aluminum foil blister packages of two tablets each. Each tablet is peach, round, bevel edged, and flat faced and embossed with “475” on one side and “WATSON” on the other side.

    Available as: Unit-of-use NDC: 52544-275-36

    Store Next ChoiceTM tablets at 20° to 25°C (68° to 77°F) [see USP controlled room temperature].

  • 17 PATIENT COUNSELING INFORMATION

    17.1 Information for Patients

    • Take Next ChoiceTM as soon as possible and not more than 72 hours after unprotected intercourse or a known or suspected contraceptive failure.
    • If you vomit within two hours of taking either tablet, immediately contact your healthcare provider to discuss whether to take another tablet.
    • Seek medical attention if you experience severe lower abdominal pain 3 to 5 weeks after taking Next ChoiceTM, in order to be evaluated for an ectopic pregnancy.
    • After taking Next ChoiceTM, consider the possibility of pregnancy if your period is delayed more than one week beyond the date you expected your period.
    • Do not use Next ChoiceTM as routine contraception.
    • Next ChoiceTM is not effective in terminating an existing pregnancy.
    • Next ChoiceTM does not protect against HIV-infection (AIDS) and other sexually transmitted diseases/infections.
    • For women younger than age 17 years, Next ChoiceTM is available only by prescription.
    • Next ChoiceTM contains FD&C Yellow #6 as a color additive.

    Manufactured by: Watson Laboratories, Inc.

    Corona, CA 92880 USA

    Distributed by: Watson Pharma, Inc.

    Corona, CA 92880 USA

    Phone: 1 -866-9WATSON (1-866-992-8766)

    www.mynextchoice.com

    Issued: August 2009

    190229-1

    0809B

  • PRINCIPAL DISPLAY PANEL


    NDC: <a href=/NDC/68258-3029-0>68258-3029-0</a>1

    NDC: 68258-3029-01

    Next Choice™ 

    (Levonorgestrel) tablets 0.75 mg 

    Emergency Contraceptive

    Reduces the chance of pregnancy after unprotected sex (if a regular birth control method fails or after sex without birth control).

    Not for regular birth control.

    Next Choice™ should be used only in emergencies.

    2 Levonorgestrel Tablets
    0.75 mg each

  • INGREDIENTS AND APPEARANCE
    NEXT CHOICE 
    levonorgestrel tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 68258-3029(NDC: 52544-275)
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LEVONORGESTREL (UNII: 5W7SIA7YZW) (LEVONORGESTREL - UNII:5W7SIA7YZW) LEVONORGESTREL0.75 mg
    Inactive Ingredients
    Ingredient NameStrength
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    POVIDONE (UNII: FZ989GH94E)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    Product Characteristics
    Colororange (peach) Scoreno score
    ShapeROUND (bevel edged, flat faced) Size6mm
    FlavorImprint Code 475;WATSON
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 68258-3029-11 in 1 CARTON
    12 in 1 BLISTER PACK
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07866509/04/2009
    Labeler - Dispensing Solutions, Inc. (066070785)
    Establishment
    NameAddressID/FEIBusiness Operations
    Dispensing Solutions, Inc.066070785relabel, repack

    • Trademark Results [Next Choice]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    NEXT CHOICE
    NEXT CHOICE
    77366454 3680666 Live/Registered
    Foundation Consumer Healthcare, LLC
    2008-01-08
    NEXT CHOICE
    NEXT CHOICE
    74194600 not registered Dead/Abandoned
    Fabco Trading Corp.
    1991-08-14
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.